Efficacy and Safety of Ivabradine Versus Beta Blockers in Inappropriate Sinus Tachycardia: A Systematic Review and Meta-Analysis

Document Type

Conference Proceeding

Publication Date

11-2-2026

Publication Title

Circulation

Abstract

Background /Objective: Inappropriate Sinus Tachycardia (IST) is characterised by an elevated resting heart rate in the absence of an identifiable cause. First-line management includes beta-blockers, however, Ivabradine has emerged as a potential alternative that may offer better symptom control with fewer side effects. This meta-analysis aims to compare the effectiveness and safety of ivabradine and beta blockers pharmacotherapy in managing IST. Methods: A systematic literature search was conducted across PubMed, Cochrane Library, Embase, ScienceDirect and Scopus from inception up to April 2025. Randomized controlled trials and observational studies reporting heart rate reduction, symptom improvement, quality of life, and adverse effects were selected. Meta-analysis was performed in R (v2025.05.0+496) using the meta package with a random-effects model. Continuous outcomes were assessed by mean difference (MD) and heterogeneity by I2 statistic with statistical significance set at p< 0.05. Results: A total of four studies comprising 416 patients with IST were included, with 121 patients receiving ivabradine and 315 receiving beta-blockers. Ivabradine led to a significantly greater reduction in heart rate compared to beta-blockers (MD: –6.89 bpm; 95% CI: -13.41 to -0.36; p = 0.0374; I2 = 69.6%). Sensitivity analysis excluding Martino et al. 2021 reduced heterogeneity (I2 = 2.4%) and maintained significance (MD: –3.23 bpm; p = 0.0187). For end heart rate, the pooled result was not statistically significant (MD: –8.08 bpm; p = 0.0958; I2 = 84.1%). However, excluding Podzolkov et al. 2022 resulted in a significant reduction favouring ivabradine (MD: –12.13 bpm; 95% CI: -22.42 to -1.84; p = 0.0208; I2 = 66.7%). Ivabradine significantly improved exercise duration (MD: +1.09 minutes; 95% CI: 0.60 to 1.57; p < 0.0001; I2 = 0.0%) and Metabolic Equivalents of Task (MD: +0.57; p = 0.0363; I2 = 0.0%). European Heart Rhythm Association (EHRA) symptom scores showed a non-significant trend toward improvement (MD: –0.36; p = 0.2131) which became significant in sensitivity analysis by excluding Martino et al. 2021 (MD: –0.60; 95% CI: -0.98 to -0.22; p = 0.0018). Conclusion: Ivabradine is more effective than beta-blockers in reducing heart rate and improving exercise capacity in patients with Inappropriate Sinus Tachycardia, with comparable safety and tolerability. These findings support its use as a preferred treatment option for IST.

Volume

154

Issue

Suppl 1

Comments

American Heart Association Scientific Sessions and the American Heart Association Resuscitation Science Symposium, November 6-9, 2026, Chicago, IL

DOI

10.1161/circ.154.suppl_1.15981

Share

COinS